ASH 2023 | Mosunetuzumab in untreated FL and MZL: a response-adapted trial
Ryan Lynch, MD, Seattle Cancer Care Alliance, University of Washington, Seattle, WA, discusses the early results of a response-adapted trial investigating the safety and efficacy of mosunetuzumab in untreated follicular lymphoma (FL) and marginal zone lymphoma (MZL). This bispecific antibody is already approved in the relapsed/refractory (R/R) FL setting, and this study provides preliminary evidence that high complete response (CR) rates are seen after 8 cycles in treatment-naïve patients, with a favorable safety profile. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: Seagen Inc., Rapt, Cyteir, Incyte, Genentech, Bayer, TG Therapeutics, Merck
Consultancy: Cancer Study Group, SeaGen, Foresight Diagnostics, Abbvie
